SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004; 172: 1297301
  • 2
    Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 33238
  • 3
    Mettlin C, Murphy GP, Lee F et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994; 152: 173740
  • 4
    Nixon RG, Wener MH, Smith KM, Parson RE, Blase AB, Brawer MK. Day to day changes in free and total PSA: significance of biologic variation. Prostate Cancer Prostatic Dis 1997; 1: 906
  • 5
    Collins GN, Martin PJ, Wynn-Davies A, Brooman PJ, O'Reilly PH. The effect of digital rectal examination, flexible cystoscopy and prostatic biopsy on free and total prostate specific antigen, and the free-to-total prostate specific antigen ratio in clinical practice. J Urol 1997; 157: 17447
  • 6
    Carter HB, Pearson JD, Waclawiw Z et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology 1995; 45: 5916
  • 7
    Eastham JA, Riedel E, Scardino PT et al. Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695700
  • 8
    Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 2002; 59: 88993
  • 9
    Roobol MJ, Kranse R, De Koning HJ, Schroder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer. results of second screening round of ERSPC (Rotterdam). Urol 2004; 63: 30915
  • 10
    Riffenburgh RH, Amling CL. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis 2003; 6: 3944
  • 11
    D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004; 351: 12535
  • 12
    Freedland SJ, Dorey F, Aronson WJ. Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology 2001; 57: 47680
  • 13
    Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994; 152: 17438
  • 14
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15917
  • 15
    Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 18215
  • 16
    Patel A, Dorey F, Franklin J, DeKernion JB. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158: 14415
  • 17
    Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 1994; 74: 6708
  • 18
    Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 21524
  • 19
    McConnell JD, Roehrborn CG, Bautista OM et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 238798
  • 20
    Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 1621
  • 21
    D’Amico AV, Moul JW, Carroll PR et al. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. J Natl Cancer Inst 2004; 96: 50915
  • 22
    Guess B, Jennrich R, Johnson H, Redheffer R, Scholz M. Using splines to detect changes in PSA doubling times. Prostate 2003; 54: 8894
  • 23
    D’Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993; 72: 263843
  • 24
    Hanks GE, D’Amico A, Epstein BE, Schultheiss TE. Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 1993; 27: 1257
  • 25
    Egawa S, Arai Y, Tobisu K et al. Use of pretreatment prostate specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 2000; 3: 26974
  • 26
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 51723
  • 27
    Partin AW, Walsh PC. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1994; 152: 1723
  • 28
    Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003; 61: 60711
  • 29
    Cher ML, Bianco FJ Jr, Lam JS et al. Limited role of radionucleotide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160: 138791
  • 30
    Okotie OT, Aronson WJ, Wieder JA et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004; 171: 22604
  • 31
    Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 132532
  • 32
    Ross JS, Jennings TA, Nazeer T et al. Prognostic factors in prostate cancer. Am J Clin Pathol 2003; 120 (Suppl.): S85100
  • 33
    Choo R, Klotz L, Deboer G, Danjoux C, Morton GC. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int 2004; 94: 2958
  • 34
    McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behaviour in patients with early untreated prostate carcinoma. Cancer 1998; 82: 3428
  • 35
    Stephenson AJ, Aprikian AG, Souhami L et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 2002; 59: 6526
  • 36
    El-Geneidy M, Garzotto M, Panagiotou I et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int 2004; 93: 5105
  • 37
    Meng MV, Elkin EP, Harlan SR, Mehta SS, Lubeck DP, Carroll PR. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol 2003; 170: 227983
  • 38
    Ross PL, Mahmud S, Stephenson AJ, Souhami L, Tanguay S, Aprikian AG. Variations in PSA doubling time in patients with prostate cancer on ‘watchful waiting’: value of short-term PSADT determinations. Urology 2004; 64: 3238
  • 39
    D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 137683
  • 40
    Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000; 48: 62933
  • 41
    Shulman MJ, Karam JA, Benaim EA. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. Urology 2004; 63: 7326
  • 42
    Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 11417
  • 43
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004; 172: S427